Curated News
By: NewsRamp Editorial Staff
September 16, 2026
VERAXA Biotech Advances Bispecific Antibody Pipeline with BiTAC Platform
TLDR
- VERAXA Biotech advances its BiTAC and VXA-222 pipelines, potentially gaining a first-mover advantage in dual-targeted cancer therapies.
- BiTAC uses AND-gated dual targeting to activate only when two tumor targets are present, reducing off-tumor toxicity.
- VERAXA's antibody therapies aim to make cancer treatment safer and more effective, improving patients' lives and outcomes.
- Did you know VERAXA's BiTAC platform requires two tumor targets to activate, making it a clever 'AND gate' for cancer therapy.
Impact - Why it Matters
This news matters because VERAXA’s AND-gated BiTAC platform could meaningfully reduce the off-tumor toxicity that has long limited the therapeutic window of antibody-based cancer treatments. By requiring two tumor-associated targets for activation, the approach may enable more precise tumor killing while sparing healthy tissue—a potential game-changer for patients with hard-to-treat cancers. The progress of the lead BiTAC-TCE into cell-line development and planned IND/CTA-enabling work, along with VXA-222’s advancement beyond antibody discovery, signals that the company is moving from concept toward clinical reality. For investors, these milestones could represent near-term catalysts and validate VERAXA’s technology platform, which is built on foundational research from the European Molecular Biology Laboratory. As the oncology landscape increasingly shifts toward smarter, more targeted immunotherapies, VERAXA’s dual-targeting strategy positions it among the innovators aiming to solve one of the field’s most persistent challenges.
Summary
VERAXA Biotech (NASDAQ: VRXA) is advancing a next-generation oncology pipeline built on engineered antibody therapies, with a sharp focus on bispecific antibody-drug conjugates (ADCs) and T-cell engagers (TCEs). At the heart of the company’s strategy is its proprietary BiTAC platform, which uses a dual-targeting “AND-gated” approach to activate therapeutic effects only when two tumor-associated targets are present on the same cancer cell. This design aims to overcome on-target, off-tumor toxicity—a persistent challenge in oncology—by preferentially targeting cancer cells while sparing healthy tissue. Early laboratory data have supported the concept across both TCE and ADC applications, and the lead BiTAC-TCE has moved into cell-line development with planned IND/CTA-enabling work following regulatory feedback from Germany’s Paul-Ehrlich-Institute.
Separately, VERAXA’s VXA-222 bispecific ADC has progressed beyond antibody discovery following a collaboration with OmniAb. The company is positioning itself as a premier engine for discovering and developing next-generation antibody-based therapeutics, guided by rigorous quality-by-design principles. Founded on scientific breakthroughs at the European Molecular Biology Laboratory, VERAXA is rapidly advancing its pipeline of ADCs and proprietary BiTAC formats into clinical development and beyond. For regular updates, visit www.VERAXA.com, and the latest news and updates relating to VRXA are available in the company’s newsroom at https://ibn.fm/VRXA. The announcement was distributed through InvestorWire, a specialized communications platform within the Dynamic Brand Portfolio @ IBN, which provides wire-grade press release syndication, editorial syndication to 5,000+ outlets, press release enhancement, social media distribution and tailored corporate communications solutions.
Source Statement
This curated news summary relied on content distributed by InvestorBrandNetwork (IBN). Read the original source here, VERAXA Biotech Advances Bispecific Antibody Pipeline with BiTAC Platform
